Virtual Reality (VR) to Improve Quality of Life in Patients Diagnosed With Neurological Disorders

Not Applicable

Completed

Brief Summary: Participants with neurological disorders will be recruited to complete sessions of virtual reality (VR) immersion. VR has been shown to have therapeutic benefit in certain patient populations and requires further clinical study to determine the extent to which VR can be used to rehabilitate and reduce symptom burden. This study seeks to pilot newly developed VR methods and collect preliminary data in order to support research grants and inform larger clinical trials. Additionally, this proposed study will explore the tolerability and preliminary efficacy of Virtual Reality (VR), specifically to determine whether VR can acutely reduce the severity of symptom burden caused by neurological disorders.

Recruitment & Eligibility

Inclusion Criteria

18-79 years of age
Has been diagnosed by a clinician as having MS
Able to commit to the designated period of testing
Able to understand the informed consent process and provide consent to participate in the study
Capacity to complete study procedures as determined by screening personnel
A Brief Pain Inventory interference score of at least 3 or more.
SDMT Z-Score > -3.0
WRAT4 Standard Score > or = 85

Exclusion Criteria

Visual, auditory, and motor deficits that would prevent full ability to understand study
Visual, auditory, and motor deficits that would prevent full ability to operate VR equipment
Uncontrolled epilepsy
Current diagnosis of vertigo
Uncontrolled mood disorders
History of Psychosis or Schizophrenia
Expanded Disability Status Scale (EDSS) Score greater than 6.5
Unable to tolerate or manipulate VR treatment procedures (as evidenced by VR capability assessment)

Primary Outcome Measures

Name	Time	Method
Change in Patient-Reported Outcomes Measurement Information System (PROMIS) - Pain Intensity - Short Form 3a Score	Baseline (Week 1), Study End (Week 5)	PROMIS - Pain Intensity - Short Form 3a consists of 3 questions -- participants report on the intensity of pain experienced in the past 7 days. Each question is scored between 1 (had no pain) to 5 (very severe). The total score range is 3-15; the higher the score, the more intense the pain.

Secondary Outcome Measures

Name	Time	Method
Change in Neuro-Quality of Life (Neuro-QOL) - Fatigue - Short Form Score	Baseline (Week 1), Treatment End (Week 4)	Neuro-QOL - Fatigue - Short Form consists of 8 statements -- participants report on fatigue symptoms experienced in the past 7 days. Each statement is scored 1 (never) to 5 (always). The total score range is 8-40; the higher the score, the more severe the fatigue.
Change in PROMIS - Fatigue Score	Baseline (Week 1), Study End (Week 5)	PROMIS-fatigue short form consists of 8 questions -- participants report on the intensity of fatigue experienced in the past 7 days. Each question is scored between 1 (had no fatigue) to 5 (always). The total score range is 8-40; the higher the score, the more intense the fatigue.
Change in Patient-Reported Outcomes Measurement Information System (PROMIS) - Sleep Related Impairment Score	Baseline (Week 1), Study End (Week 5)	PROMIS - Sleep Related Impairment consists of 16 items. Participants report on sleep related impairment experienced in the past 7 days. Each statement is scored between 1 (not at all) and 5 (very much). The total score range is 16-80; the higher the score, the higher the level of sleep related impairment.

Locations (1): New York University School of Medicine
🇺🇸
New York, New York, United States
New York University School of Medicine
🇺🇸New York, New York, United States